Atara Biotherapeutics

ATA188, an experimental cell therapy targeting the Epstein-Barr virus, failed to outperform a placebo at easing disability levels in people with nonactive progressive forms of multiple sclerosis (MS), according to data from the Phase 2 portion of the EMBOLD clinical trial. The medication also showed no signs of…

The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of multiple sclerosis, according to the data, now reaching up to four years, on patients in an ongoing clinical trial. People who achieved confirmed disability improvement also showed potential signs of remyelination, or…

EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead Is this another small step toward an MS cure? AT188 is an experimental therapy designed to kill cells infected with the Epstein-Barr virus (EBV). As you probably know, researchers have found a lot of evidence that EBV is connected…

An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…

The National Institutes of Health (NIH) is joining the search for a vaccine to attack the Epstein-Barr virus (EBV). This is a big deal for people with multiple sclerosis, because carrying the virus is thought to play a significant role in the development of MS. In fact,…

Progressive MS Trial Finds Repeat Bone Marrow Infusion Safe, Feasible Two bone marrow transplant studies are reported in this story. The first, a tiny trial of just six people, assessed the safety of this procedure, which involves harvesting cells from their bone marrow, then infusing them into the bloodstream…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

Atara Biotherapeutics has reached an agreement with Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including ATA188, an experimental therapy being investigated for the treatment of progressive multiple sclerosis (MS). Under the agreement, Fujifilm will acquire Atara’s T-Cell Operations and Manufacturing (ATOM) facility in Thousand…

Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The imaging technology will be used to determine if Atara’s ATA188…

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

ATA188, Atara Biotherapeutics’ investigative T-cell immunotherapy, is safe, well tolerated, and able to ease disability and improve exercise capacity in patients with progressive forms of multiple sclerosis (MS), according to one-year data from a Phase 1 trial and its long-term extension study. Findings also showed that, after…

Atara Biotherapeutics has enrolled a first patient in a clinical trial testing ATA188, its off-the-shelf T-cell immunotherapy for people with progressive forms of multiple sclerosis (MS). The Phase 1b trial (NCT03283826) follows promising safety and tolerability results from its open-label Phase 1a part, including a…

Atara Biotherapeutics‘ cell-based therapy ATA188 is safe and well-tolerated in people with progressive forms of multiple sclerosis (MS), and induces a sustained reduction in disability in a dose-dependent manner, findings from the first part of a Phase 1 clinical trial show. ATA188 had an…

In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of its ongoing Phase 1 clinical trial investigating ATA188 in people with progressive forms of multiple sclerosis (MS). People treated in the first, open-label part of this trial, however,…

People with progressive forms of multiple sclerosis (MS) and past exposure to the Epstein-Barr virus are responding to a potential immunotherapy known as ATA188, tolerating the treatment well and with signs that suggest effectiveness, early updated data from an ongoing Phase 1 trial show. The research, “…

Early, positive safety results from a Phase 1 trial testing a potential immunotherapy, ATA188, in people with progressive multiple sclerosis will be detailed at the 5th Congress of the European Academy of Neurology (EAN) late next month, its developer, Atara Biotherapeutics, announced. ATA188 is an investigational and “off-the-shelf”…

Atara Biotherapeutics’ investigational ATA190, a cell therapy that wipes out immune B-cells infected with the Epstein-Barr virus (EBV), led to neurological improvements and reduced symptoms in patients with primary and secondary progressive multiple sclerosis (MS), a Phase 1 trial shows. The trial results were published in the Journal…

Analysis of post-mortem brain samples from multiple sclerosis (MS) patients and healthy individuals (without neurologic disease) showed that while signs of Epstein-Barr virus (EBV) infection are present in both groups of brains, EBV-positive immune cells were more prevalent and densely populated in the MS brain. The study reporting those findings,…

Atara Biotherapeutics has received a green light to enroll U.S. patients into a Phase 1 trial of ATA188 for progressive or relapsing-remitting multiple sclerosis (MS). The study was initially launched in Australia, but with the U.S. Food and Drug Administration (FDA) having cleared the company’s application, the trial…

Atara Biotherapeutics has started a Phase 1 clinical trial to assess ATA188’s safety and potential to treat progressive or relapsing-remitting multiple sclerosis. ATA188 is the company’s next-generation T-cell immunotherapy. It targets Epstein-Barr virus antigens that play an important role in the development of MS. An antigen is a molecule capable of…

Atara Biotherapeutics recently published an update of the company’s quarterly financial results and operational highlights, including the advancement of its T-cell based immunotherapy strategies for multiple sclerosis (MS) and cancer. One of the investigational therapies featured in the report is ATA188, a potential treatment for MS.

An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple sclerosis treatment, a Phase 1 clinical trial involving a small patient group indicates. The trial, conducted in Australia, covered six people with primary or secondary progressive MS. B-cells are a…